Wednesday 19th March - Main Conference Day One - PT (Pacific Time, GMT-08:00)
- Hamza Ahsan - Senior Manager, MSAT, Vaxcyte, Inc.
- Wenjun Di - Senior Scientist, Downstream Process and Formulation Development, Ultragenyx Pharmaceutical Inc.
We present a novel pilot-scale benchtop system that can run almost all major downstream purification processes, such as chromatography, tangential flow filtration (TFF), SPTFF, normal flow filtration, inline dilution, and various process intensifications (4C) and integrated processes. This platform features its powerful multi functionality with three key innovative process configurations and modular concept as well as a comprehensive industrial DCS control and data management framework in line with digital transformation. The system represents a transformative shift in bio pharmaceutical downstream processing and can play a critical POC role for tech transfer.
- Zuwei Jin - VP Business Development, Lisure Technologies
- Manuel Carrondo - Vice-President, Instituto de Biologia Experimental e Tecnológica
- Ryan Murray - Senior Consultant, ValSource Inc.
- Kate Rochlin - Chief Operating Officer, IN8bio
In this lunch workshop, we’ll explore top considerations as you prepare your process development organization for the next wave of digital and AI maturity. Through a mix of real world examples and live product demonstration, we’ll touch on key topics such as:
Generating a scalable data foundation for process development
Building user-friendly digital workflows that encourage adoption, efficiency, and AI-ready data
Putting AI to work for both scientific and operational acceleration
- Michael Schwartz - Process Development Strategy, Benchling
The biopharmaceutical industry faces increasing pressure to produce a wide range of therapeutics quickly, with high yields and consistent quality. Lonza helps companies meet these demands with integrated solutions that streamline the entire drug development process. By combining cutting-edge expression technology, efficient CHO media systems, and expert biologics services, we support drug developers and producers from late-stage discovery all the way to commercial supply.
At the core of our solutions is the proven GS® platform, designed to deliver high-yield, scalable, and stable expression for a broad range of biotherapeutics. With this platform, we help you optimize the expression of your molecule, whatever its type, helping to reduce time to market.
Supporting this, the TheraPRO® CHO Media System offers a chemically defined, non-animal origin (NAO) formulation, solution engineered to maximize protein yield and ensure scalability across research and manufacturing stages. Its advanced formulation delivers consistent performance and simplifies workflows, backed by proven performance for modern bioprocessing needs.
Lonza’s biologics services further offer end-to-end solutions for any molecule type. These services encompass drug candidate selection & optimization, process development, clinical and commercial manufacturing, and regulatory support, helping customers reach the clinic and market faster.
In this talk, we'll cover how our proven GS® platform, CHO media, and expertise in biologics enable biopharmaceutical companies to efficiently bring scalable, high-quality therapies to market, transforming scientific innovation into life-changing treatments for patients.
- Sanjay Kumar - Head of Technical Excellence, Media Solutions, Lonza Bioscience
- Manuel Carrondo - Vice-President, Instituto de Biologia Experimental e Tecnológica
- Kendall Feshuk - Global Head, Membership Development & Solutions, Rx-360, USA
- Lakshman Prakash Balajepalli - Manage QA, Cedars Sinai Biomanufacturing Center, USA
- Hui-Lan Hu - Associate principle scientist, AstraZeneca
- Yuansheng Yang - Senior Principle Scientist 1, A*STAR
- Larry Forman - CEO, CHO PLUS
- Stephen Zano - Director, Early Research and Process Development, Sarepta Therapeutics
- Jesse Richter - Executive Director, Tech Transfer and Validation - Global Technical Operations, Biopharmaceuticals, AstraZeneca
- Noman Khan - Associate Director External Engagement, University of Utah
- Abdul Mukati - CEO and Founder, Master Inbox
Novel modalities propose unique challenges for their purification and removal of impurities - how can purification processes be optimized for these novel modalities?
- Downstream processing considerations for modalities such RNA-based-therapies, T-cell engagers, CGTs.
- Key challenges in purification, scaling, and quality control.
- Innovative solutions and strategies for optimizing these processes.
- Jolene Ignowski, Ph.D - CMC Project Lead, Bayer
- Maher Alayyoubi - Senior Principal Scientist - RNA Technology and Innovation, Arcturus Therapeutics
- Alpana Naresh, Ph.D. - VP, CMC Manufacturing, Hinge Bio, Inc.
- Amy Shaw - Head of Process and Product Development, Cell Therapy Sciences, Takeda, USA
- Jose Vidal - CEO, CytoImmune Therapeutics Puerto Rico, LLC
- Dan Stanton - Editorial Director, Informa Connect Life Sciences
- Adapting to Change – How can manufacturers design and operate facilities to quickly pivot in response to market demands, supply chain disruptions, or technological advancements?
- Future-Proofing Manufacturing – Strategies to integrate modular design, scalable systems, and adaptable infrastructure that support evolving operational needs while maintaining efficiency.
- Bridging Design, Operations, and Quality – How can cross-functional collaboration between design, operations, QA, and QC create a manufacturing ecosystem that is flexible, compliant, and resilient?
- Operational Agility in Action – Exploring workflow optimization, lean manufacturing principles, automation, and digital tools that empower operations teams to adapt without sacrificing quality or throughput.
- Lessons from the Field – Hear real-world insights from design, operations, QA, and QC professionals on balancing efficiency, compliance, and flexibility in manufacturing.
- Join us for this dynamic discussion and gain actionable insights on designing and operating for adaptability in modern manufacturing!
- Levi Williams - Principal Consultant, Coastline Biotech Solutions
- Katharine Chastain - Biotech QC & Operations Leader, Cibus
- Fiona Stack - Principal consultant, Coastline Biotech Solutions
- Kevin Chriswell - Vice President | Science + Technology, CannonDesign
- Amanda Allen - Executive Director of Operations and Facilities, Odyssey Therapeutics
- Rod Mazandarani - Science & Technology Practice Leader, Cannon Design
• How diverse perspectives contribute to innovation in research, development, and commercialization.
• Creating equitable opportunities for career advancement and inclusive leadership.
• Sharing experiences and best practices for fostering a culture of belonging in the workplace.
- Tyler Brown - Chair/President, OUTBio San Diego
- Hooriya Hussain - National Board of Governors, Human Rights Campaign